Effect of Gender Affirming Hormone Therapy on Glucose Metabolism

Description

The study will test: 1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function 2. whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function 3. whether estrogen therapy leads to enhanced immune response in older transwormen

Conditions

Transgender Persons

Talk to us

Study Overview

On this page

Study Details

Study overview

The study will test: 1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function 2. whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function 3. whether estrogen therapy leads to enhanced immune response in older transwormen

Effect of Gender Affirming Hormone Therapy on Glucose Metabolism

Effect of Gender Affirming Hormone Therapy on Glucose Metabolism

Condition
Transgender Persons
Intervention / Treatment

-

Contacts and Locations

San Antonio

Bartter Clinical Research Unit, Audie L. Murphy VA Hospital, sTXVHCS, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Healthy volunteers: healthy male or female
  • * MTF transgender
  • * FTM transgender
  • * Non-diabetic (A1c\<6.5%), fasting glucose \<126mg/dl and OGTT after 2 hr \<200mg/dl)
  • * Stable hormone treatment (estrogen or testosterone) for at least 6 months
  • * History of or newly diagnosed diabetes mellitus
  • * For healthy volunteers, not current treatment with estrogen or testosterone
  • * For FTM transgender, no recent cardiovascular event: acute coronary syndrome (ACS), stroke (CVA)
  • * For MTF and FTM transgender, less than 6 months of stable hormone treatment
  • * Anemia with hemoglobin (Hb) \<11.0 hematocrit (Hto) \< 34 and Glomerular Filtration rate (GFR) \<30

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

The University of Texas Health Science Center at San Antonio,

Devjit Tripathy, MD, PRINCIPAL_INVESTIGATOR, University of Texas Health San Antonio

Study Record Dates

2025-07